These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 21963369)

  • 21. Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications.
    Vlček P; Polák J; Brunovský M; Horáček J
    Pharmacopsychiatry; 2018 Nov; 51(6):229-242. PubMed ID: 28950396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. N-Acetyl Cysteine and Vitamin D Supplementation in Treatment Resistant Obsessive-compulsive Disorder Patients: A General Review.
    di Michele F; Siracusano A; Talamo A; Niolu C
    Curr Pharm Des; 2018; 24(17):1832-1838. PubMed ID: 29663874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glutamate drugs and pharmacogenetics of OCD: a pathway-based exploratory approach.
    Grados MA; Specht MW; Sung HM; Fortune D
    Expert Opin Drug Discov; 2013 Dec; 8(12):1515-27. PubMed ID: 24147578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Gonadal Hormones on Neurotransmitters Implicated in the Pathophysiology of Obsessive-Compulsive Disorder: A Critical Review.
    Karpinski M; Mattina GF; Steiner M
    Neuroendocrinology; 2017; 105(1):1-16. PubMed ID: 27894107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in the neurobiology of obsessive-compulsive disorder. Implications for conceptualizing putative obsessive-compulsive and spectrum disorders.
    Stein DJ
    Psychiatr Clin North Am; 2000 Sep; 23(3):545-62. PubMed ID: 10986727
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain imaging in pediatric obsessive-compulsive disorder.
    MacMaster FP; O'Neill J; Rosenberg DR
    J Am Acad Child Adolesc Psychiatry; 2008 Nov; 47(11):1262-72. PubMed ID: 18827717
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder.
    Bhattacharyya S; Khanna S; Chakrabarty K; Mahadevan A; Christopher R; Shankar SK
    Neuropsychopharmacology; 2009 Nov; 34(12):2489-96. PubMed ID: 19675532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is glutamate associated with fear extinction and cognitive behavior therapy outcome in OCD? A pilot study.
    Giménez M; Cano M; Martínez-Zalacaín I; Real E; Alonso P; Segalàs C; Munuera J; Kegeles LS; Weinstein JJ; Xu X; Menchón JM; Cardoner N; Soriano-Mas C; Fullana MA
    Eur Arch Psychiatry Clin Neurosci; 2020 Dec; 270(8):1003-1014. PubMed ID: 31432262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutamate modulators in the treatment of obsessive-compulsive disorder.
    Pittenger C
    Psychiatr Ann; 2015 Jun; 45(6):308-315. PubMed ID: 26236057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review and meta-analysis: Memantine augmentation in moderate to severe obsessive-compulsive disorder.
    Modarresi A; Chaibakhsh S; Koulaeinejad N; Koupaei SR
    Psychiatry Res; 2019 Dec; 282():112602. PubMed ID: 31630042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New pathophysiological approaches to obsessive-compulsive disorder].
    Benzina N
    Rev Prat; 2020 Sep; 70(7):779-782. PubMed ID: 33739728
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obsessive-compulsive disorder: an integrative genetic and neurobiological perspective.
    Pauls DL; Abramovitch A; Rauch SL; Geller DA
    Nat Rev Neurosci; 2014 Jun; 15(6):410-24. PubMed ID: 24840803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipsychotic treatment in obsessive-compulsive disorder: a literature review.
    Keuneman RJ; Pokos V; Weerasundera R; Castle DJ
    Aust N Z J Psychiatry; 2005 May; 39(5):336-43. PubMed ID: 15860020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered serotonergic and GABAergic neurotransmission in a mice model of obsessive-compulsive disorder.
    Winter C; Greene DM; Mavrogiorgou P; Schaper H; Sohr R; Bult-Ito A; Juckel G
    Behav Brain Res; 2018 Jan; 337():240-245. PubMed ID: 28916503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuroscientifically Informed Formulation and Treatment Planning for Patients With Obsessive-Compulsive Disorder: A Review.
    Dougherty DD; Brennan BP; Stewart SE; Wilhelm S; Widge AS; Rauch SL
    JAMA Psychiatry; 2018 Oct; 75(10):1081-1087. PubMed ID: 30140845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Striatal structure and its association with N-Acetylaspartate and glutamate in autism spectrum disorder and obsessive compulsive disorder.
    Naaijen J; Zwiers MP; Forde NJ; Williams SC; Durston S; Brandeis D; Glennon JC; The Tactics Consortium ; Franke B; Lythgoe DJ; Buitelaar JK
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):118-129. PubMed ID: 29169826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Abnormalities in metabolite concentrations in tourette's disorder and obsessive-compulsive disorder-A proton magnetic resonance spectroscopy study.
    Fan S; Cath DC; van den Heuvel OA; van der Werf YD; Schöls C; Veltman DJ; Pouwels PJW
    Psychoneuroendocrinology; 2017 Mar; 77():211-217. PubMed ID: 28104554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder.
    Yücel M; Wood SJ; Wellard RM; Harrison BJ; Fornito A; Pujol J; Velakoulis D; Pantelis C
    Aust N Z J Psychiatry; 2008 Jun; 42(6):467-77. PubMed ID: 18465373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fronto-Striatal Glutamate in Autism Spectrum Disorder and Obsessive Compulsive Disorder.
    Naaijen J; Zwiers MP; Amiri H; Williams SCR; Durston S; Oranje B; Brandeis D; Boecker-Schlier R; Ruf M; Wolf I; Banaschewski T; Glennon JC; Franke B; Buitelaar JK; Lythgoe DJ
    Neuropsychopharmacology; 2017 Nov; 42(12):2456-2465. PubMed ID: 27869141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Neurobiological Underpinnings of Obsessive-Compulsive Symptoms in Psychosis, Translational Issues for Treatment-Resistant Schizophrenia.
    Vellucci L; Ciccarelli M; Buonaguro EF; Fornaro M; D'Urso G; De Simone G; Iasevoli F; Barone A; de Bartolomeis A
    Biomolecules; 2023 Aug; 13(8):. PubMed ID: 37627285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.